Author:
Dudău Mădălina,Alexandru Cristina,Bobircă Florin,Ioan Ancuţa,Bojincă Mihai,Bobircă Anca
Reference10 articles.
1. Vonk MC. Is there still a role for cyclophosphamide in the treatment of systemic sclerosis? Journal of Scleroderma and Related Disorders. 2021 Jun;6(2):117-122. doi:10.1177/2397198320961673. PMID:35382095; PMCID:PMC8892929.
2. Valentini G, Paone C, La Montagna G, Chiarolanza I, Menegozzo M, Colutta E, Ruocco L. Low‐dose intravenous cyclophosphamide in systemic sclerosis: an open prospective efficacy study in patients with early diffuse disease. Scandinavian Journal of Rheumatology. 2006;35:1,35-38, DOI:10.1080/03009740510026896.
3. Ogino MH, Tadi P. Cyclophosphamide. [Updated 2022 Jul 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK553087/
4. Owen C, Ngian GS, Elford K, et al. Mycophenolate mofetil is an effective and safe option for the management of systemic sclerosis-associated interstitial lung disease: results from the Australian Scleroderma Cohort Study. Clin Exp Rheumatol. 2016;34 Suppl 100(5):170-176. https://pubmed.ncbi.nlm.nih.gov/27049330/
5. Nihtyanova SI, Brough GM, Black CM, Denton CP. Mycophenolate mofetil in diffuse cutaneous systemic sclerosis – a retrospective analysis. Rheumatology (Oxford). 2007;46(3):442-445. doi:10.1093/rheumatology/kel244.